Q1 Earnings Forecast for AnaptysBio Issued By HC Wainwright

AnaptysBio, Inc. (NASDAQ:ANAB) – Analysts at HC Wainwright dropped their Q1 2025 EPS estimates for shares of AnaptysBio in a report released on Wednesday, February 12th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings per share of ($1.56) for the quarter, down from their prior estimate of ($1.44). HC Wainwright currently has a “Neutral” rating and a $19.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q2 2025 earnings at ($1.65) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.85) EPS, FY2025 earnings at ($6.79) EPS, FY2026 earnings at ($6.19) EPS, FY2027 earnings at ($10.60) EPS and FY2028 earnings at ($10.49) EPS.

ANAB has been the subject of several other reports. Guggenheim lowered their price objective on AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. UBS Group boosted their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Wedbush reiterated an “outperform” rating and issued a $40.00 price target on shares of AnaptysBio in a report on Wednesday, February 12th. Finally, Wolfe Research assumed coverage on AnaptysBio in a research note on Tuesday, February 4th. They set an “outperform” rating and a $25.00 price target on the stock. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.45.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $19.78 on Monday. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $41.31. The firm has a market capitalization of $601.91 million and a PE ratio of -3.25. The business’s fifty day moving average price is $15.71 and its 200 day moving average price is $25.54.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently modified their holdings of the company. nVerses Capital LLC grew its stake in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio during the 3rd quarter valued at $49,000. China Universal Asset Management Co. Ltd. raised its position in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after buying an additional 2,600 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in AnaptysBio in the third quarter valued at $574,000.

Insider Transactions at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction on Thursday, January 2nd. The shares were bought at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the acquisition, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 33.70% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.